Results 31 to 40 of about 67,462 (301)

Use of Right Ventricular Assist Device Post-Left Ventricular Assist Device Placement

Hearts
Right heart failure (RHF) is a common manifestation after left ventricular assist device (LVAD) placement and is associated with a high mortality rate. Historically, RV failure requiring an RVAD at the time of LVAD implantation has been associated with ...
Shannon Parness, Tori E. Hester, Harish Pandyaram, Panagiotis Tasoudis, Aurelie E. Merlo   +4 more
doaj   +1 more source

Targeted myocardial gene expression in failing hearts by RNA sequencing

Journal of Translational Medicine, 2016
Background Myocardial recovery with left ventricular assist device (LVAD) therapy is highly variable and difficult to predict. Next generation ribonucleic acid (RNA) sequencing is an innovative, rapid, and quantitative approach to gene expression ...
Kajari Dhar, Alexandra M. Moulton, Eric Rome, Fang Qiu, Jeff Kittrell, Eugenia Raichlin, Ronald Zolty, John Y. Um, Michael J. Moulton, Hesham Basma, Daniel R. Anderson, James D. Eudy, Brian D. Lowes   +12 more
doaj   +1 more source

Ventricular assist devices

Continuing Education in Anaesthesia Critical Care & Pain, 2012
Heart failure occurs in 1% of the UK adult population yet represents 5% of all hospital admissions, according to the 2008/09 National Heart Failure audit (http://www.ic.nhs.uk/ webfiles/publications/002_Audits/NHS_IC_ HEART_FAILURE_AUDIT_13-12-10.pdf ).
Paul Harris, Lakshminarasimhan Kuppurao
openaire   +2 more sources

Successful bridge to recovery in fulminant myocarditis using a biventricular assist device: a case report

Journal of Medical Case Reports, 2017
Background Fulminant myocarditis is a life-threatening disease, and myocardial damage expands the right ventricle as well as the left ventricle in some cases.
Yusuke Adachi, Osamu Kinoshita, Masaru Hatano, Yukako Shintani, Noritsugu Naito, Mitsutoshi Kimura, Kan Nawata, Daisuke Nitta, Hisataka Maki, Kazutaka Ueda, Eisuke Amiya, Eiki Takimoto, Issei Komuro, Minoru Ono   +13 more
doaj   +1 more source

Heart Failure Anticoagulation Teach-Back Education and Readmissions [PDF]

, 2020
: Heart failure affects millions of Americans each year. Treatment of advanced heart failure with reduced ejection fraction and left ventricular failure is sometimes treated with implantation of a left-ventricular assist device.

core  

Cutting the Cord: A Case of Late Presenting Driveline Infection [PDF]

, 2020
Ventricular assist device (VAD) related infection, specifically driveline infection, is a common complication after VAD implantation. A 45-year old patient with a delayed skin infection at the site of the original driveline nearly one year after VAD ...
Eyadiel, Lauren, Laughey, Brian, Pisani, Barbara   +2 more
core   +1 more source

Experience with left ventricular assist device usage in the treatment of end-stage heart failure [PDF]

Кардіохірургія та інтервенційна кардіологія, 2017
Heart failure potentially developing in most of heart diseases is a progressive process associated with high morbidity and mortality. Almost 3/4 of patients die within five years after first hospitalization because of heart failure.
B.M. Todurov, G.I. Kovtun, I.M. Kuzmich, M.V. Goncharenko, A.M. Druzhyna, A.O. Shpachuk, O.M. Postupalsky, S.O. Sheludko, S.M. Sudakevych, O.V. Stanyshevskyi, A.Yu. Melnyk   +10 more
doaj  

Ethical challenges with the left ventricular assist device as a destination therapy

Philosophy, Ethics, and Humanities in Medicine, 2008
The left ventricular assist device was originally designed to be surgically implanted as a bridge to transplantation for patients with chronic end-stage heart failure.
Rady Mohamed Y, Verheijde Joseph L, Rizzieri Aaron G, McGregor Joan L   +3 more
doaj   +1 more source

Design and characteristics of the prophylactic intra‐operative ventricular arrhythmia ablation in high‐risk LVAD candidates (PIVATAL) trial

Annals of Noninvasive Electrocardiology, 2023
Background The use of a Left Ventricular Assist Device (LVAD) in patients with advanced heart failure refractory to optimal medical management has progressed steadily over the past two decades. Data have demonstrated reduced LVAD efficacy, worse clinical
David T. Huang, Igor Gosev, Katherine L. Wood, Hima Vidula, William Stevenson, Frank Marchlinski, Gregory Supple, Sandip K. Zalawadiya, J. Peter Weiss, Roderick Tung, Wendy S. Tzou, Joshua D. Moss, Krishna Kancharla, Sunit‐Preet Chaudhry, Parin J. Patel, Arfaat M. Khan, Claudio Schuger, Guy Rozen, Michael S. Kiernan, Gregory S. Couper, Marzia Leacche, Ezequiel J. Molina, Anand D. Shah, Michael Lloyd, Jakub Sroubek, Edward Soltesz, Kalyanam Shivkumar, Casey White, Sinan Tankut, Brent A. Johnson, Scott McNitt, Valentina Kutyifa, Wojciech Zareba, Ilan Goldenberg   +33 more
doaj   +1 more source

Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the value of MRI outcomes as endpoints for preventive and early‐stage trials of two polyglutamine spinocerebellar ataxias (SCAs). Methods A cohort of 100 participants (23 SCA1, 63 SCA3, median Scale for the Assessment and Rating of Ataxia (SARA) score = 5, 42% preataxic, and 14 gene‐negative controls) was scanned at 3T up ...
Thiago J. R. Rezende, Emilien Petit, Young Woo Park, Sophie Tezenas du Montcel, James M. Joers, Jonathan M. DuBois, H. Moore Arnold, Michal Povazan, Ipek Özdemir, Guita Banan, Romain Valabregue, Philipp Ehses, Jennifer Faber, Chiadi U. Onyike, Peter B. Barker, Jeremy D. Schmahmann, Eva‐Maria Ratai, Sub H. Subramony, Thomas H. Mareci, Khalaf O. Bushara, Henry Paulson, Thomas Klockgether, Alexandra Durr, Tetsuo Ashizawa, Christophe Lenglet, Gülin Öz, READISCA Investigators   +26 more
wiley   +1 more source